


# 3D Human airway epithelial models to study SARS-CoV-2 pathogenesis and to discover antivirals

Samuel Constant, Ph.D., CEO  
[samuel.constant@epithelix.com](mailto:samuel.constant@epithelix.com)

ASCCT/ESTIV, 17/03/2022



December 2019

- ✓ First cases recognized

January 2020

- ✓ Genome revealed + PCR diagnostic published

March 2020


- ✓ Antibody tests

May 2020


- ✓ First Antiviral Authorization (FDA) for emergency use (Remdesivir)

March 17<sup>th</sup> 2022

- ✓ 5 vaccines authorized in the EU (EMA)
- ✓ 2 Antivirals authorized: Paxlovid (FDA and EMA) and Molnupiravir (FDA)
- ✓ > 400'000 research articles on COVID-19 (WHO database)
- ✓ > 457 M Cases reported
- ✓ > 6 M deaths (1.3 % death rate)




# SARS-CoV-2 Structure





- Virion diameter : 50–200 nanometers
- S, E and M proteins form the viral envelope
- N protein holds the RNA genome
- Spike S protein allow the virus to attach to and fuse with the membrane of a host cell



# The virus entry: Angiotensin-converting Enzyme-2 (ACE2) receptor




# Chronology of events during SARS-CoV-2 infection




# Chronology of events during SARS-CoV-2 infection




# In vitro 3D human airway epithelia



# MucilAir™ & SmallAir™ : Long shelf life in vitro Airway models




# In vitro Antiviral Testing using MucilAir™ and SmallAir™




## Rhinovirus

HRV-A16  
HRV-B14  
HRV-C15




## Coronavirus

OC 43  
SARS-CoV-2




## Influenza

Influenza A  
(H1N1 and H3N2)  
Influenza B




## Respiratory Syncytial Virus

RSV-A  
RSV-B



## Respiratory Enterovirus


EV-68



## Others

Metapneumovirus  
Parainfluenza virus 3


# ACE2 is expressed in MucilAir™ and SmallAir™





- SmallAir™ SA068001: Small-Airways
- MucilAir™ MD074201: Nasal
- MucilAir™ MD078701: Bronchial

MucilAir™ and SmallAir™ express ACE2 mRNA at high levels


# Efficient replication of SARS-CoV-2 in MucilAir™



0 10 20 30 40 50  $\mu\text{m}$





# SARS-CoV-2 cell tropism






SARS-CoV-2 infects mainly ciliated and goblet cells

# SARS-CoV-2 impairs cilia function




SARS-CoV-2 impairs mucociliary clearance on MucilAir™


# Innate immune transcriptional signature induced by SARS-CoV-2 on MucilAir™



Strong upregulation of type I and III interferons and genes associated with NF- $\kappa$ B and TNF- $\alpha$  is observed


# Current research strategies to stop SARS-CoV-2 infection






Aerosol therapies or systemic delivery can be easily studied

# Antiviral evaluation of novel therapies against SARS-CoV-2 on MucilAir™



Molnupiravir and Paxlovid inhibit efficiently SARS-CoV-2 replication


# Antiviral evaluation of combos against SARS-CoV-2 on MucilAir™



Combination therapy can enhance the antiviral activity of Molnupiravir

# Models Predictivity: Case of Hydroxychloroquine


Vero E6 cells



HCQ is effective

$IC_{50} = 2.2 \mu M$  (48h pi)  
-  $4.4 \mu M$  (72h pi)

MucilAir™



HCQ is not effective at  
subtoxic doses

Cynomolgus  
Macaques



HCQ is not effective  
against SARS-CoV-2

## Conclusion

**ALI 3D Human Airway Models like MucilAir™ and SmallAir™ are useful tools to study SARS-CoV-2 pathogenesis**

- ✓ Isolation, characterization and amplification of circulating strains
- ✓ Identification of transcriptional and secreted innate immune signature
- ✓ Pathway identification of the pathogenesis
- ✓ Screening platform to test antivirals (repositioning of marketed drugs or evaluation of novel therapies and combinations delivered systematically or through aerosol therapy) -> **Local toxicity & efficacy assessment!**


# Thanks for your attention

 **French Lab**

- Carole Bertinetti
- Mendy Bouveret
- Christine CaulFuty
- Mireille CaulFuty
- Ophélie Verbeke
- Laurent Wiszniewski
- Dr. Ludovic Wiszniewski

 **Swiss Lab**

- Paul Alouani
- Guy Barbin
- Sacha Benaoudia
- Dr. Bernadett Boda
- Rosy Bonfante
- Caroline Chojnacki
- Cindia Ferreira
- Emilie Ferreira
- Ina Fureraj
- Matia Gojun
- Dr. Song Huang
- Xiao-Yann Huang
- Faten Hussein
- Gowsinth Gunasingam
- Marc Lanzillo
- Melany Monachino
- Rebecca Pimenta
- Florian Shala
- Jimmy Vernaz
- Karin Weber



▪ Dr. Manuel Rosa-Calatrava

▪ Dr. Olivier Terrier



▪ Prof. Caroline Tapparel

▪ Dr. Manel Essaidi-Laziosi



▪ Dr. Olivier Engler

▪ Dr. Hulda Jonsdottir

BILL & MELINDA  
GATES foundation

▪ Dr. Rob Jordan

▪ Dr. Monalisa Chatterji

Interested in new updates on *in vitro* lung models approaches ?



13-14 JUNE NICE - FRANCE

LIVE 2022  
**LUNG IN VITRO** event  
for innovative & predictive models